SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(RULE 14d-100)
TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF
THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO.____)
AND
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1)
Laboratorio Chile S.A.
(Name of Subject Company (Issuer))
IVAX Holdings C.I.
a wholly-owned Subsidiary of
IVAX Corporation
(Name of filing Persons (Offerors))
American Depositary Shares
(Each Representing 20 Shares of Common Stock)
Common Stock, no par value
(Titles of Classes of Securities)
(50540H104) American Depositary Shares
(P61210106) Common Stock
(CUSIP Numbers of Classes of Securities)
Adrianne Fauz Cornejo, Esq.
Associate General Counsel
IVAX Corporation
4400 Biscayne Boulevard
Miami, Florida 33137
(305) 575-6000
(Name, Address and Telephone Number of
Person Authorized to Receive Notices
and Communications on Behalf of the
Person(s) Filing Statement)
COPIES TO:
Jose Maria Eyzaguirre. Esq.
Laurie Green, Esq. Matias de Marchena, Esq.
Kara L. MacCullough, Esq. Claro y Cia.
Akerman, Senterfitt & Eidson, P.A. Apoquindo 3721 - 13th floor
SunTrust International Center, 28th Floor P.O. Box 1867
One Southeast Third Avenue Postal Code 6760352
Miami, Florida 33131-1714 Santiago Chile
(305) 374-5600 (56-2) 367 30 00
================================================================================
TRANSACTION VALUATION AMOUNT OF FILING FEE
- --------------------------------------------------------------------------------
$ 518,350 $ 104
================================================================================
(1) The filing fee has been calculated pursuant to Rule 0-11(d) under the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), based upon
U.S. $25.00 per American Depositary Share ("ADS") with respect to 20,734
outstanding ADSs as of July 30, 2001, excluding ADSs beneficially owned by IVAX
Corporation ("IVAX") or its affiliates. The number of outstanding ADSs is based
upon information provided to the bidder by Laboratorio Chile S.A. ("LabChile").
Based upon information provided to the bidder by LabChile, there are no shares
of common stock, no par value (the "Shares"), excluding Shares represented by
ADSs and Shares beneficially owned by IVAX or its affiliates, held by U.S.
holders, as defined in Rule 14d-1(d) under the Exchange Act. Therefore, no fee
is being paid with respect to the acquisition of Shares.
[_] Check box if any part of the fee is offset as provided by Rule 0-11(a)(2)
and identify the filing with which the offsetting fee was previously
paid. Identify the previous filing by registration statement number on
the Form or Schedule and the date of its filing.
Amount Previously Paid: N/A Filing Party: N/A
Form or Registration No.: N/A Date Filed: N/A
[_] Check the box if the filing relates solely to preliminary communication
made before the commencement of a tender offer.
Check the appropriate boxes below to designate any transactions to which
the statement relates:
[X] third-party tender offer subject to Rule 14d-1.
[_] issuer tender offer subject to Rule 13e-4.
[_] going-private transaction subject to Rule 13e-3.
[X] amendment to Schedule 13D under Rule 13d-E
[_] Check the following box if the filing is a final amendment reporting the
results of the tender offer:
- ------------------------
CUSIP Nos. 50540H104 and
P6121Q106
- ------------------------
- --------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
IVAX Corporation
- --------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
2
(b) [X]
- --------------------------------------------------------------------------------
SEC USE ONLY
3
- --------------------------------------------------------------------------------
SOURCE OF FUNDS
4
WC
- --------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
5 2(d) or 2(e) [_]
- --------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Florida
- --------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 252,259,699 Shares of common stock (including Shares
represented by ADSs)
-------------------------------------------------------------
SHARES SHARED VOTING POWER
8
BENEFICIALLY 62,565,840 Shares of common stock (including Shares
represented by ADSs)
OWNED BY -------------------------------------------------------------
SOLE DISPOSITIVE POWER
EACH 9
252,259,699 Shares of common stock (including Shares
represented by ADSs)
REPORTING -------------------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10
62,565,840 Shares of common stock (including Shares
WITH represented by ADSs)
- --------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
314,825,539 Shares of common stock (including Shares represented by ADSs)
- --------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_]
12
- --------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
99.6%
- --------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
- --------------------------------------------------------------------------------
- ------------------------
CUSIP Nos. 50540H104 and
P6121Q106
- ------------------------
- --------------------------------------------------------------------------------
NAMES OF REPORTING PERSONS
1 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
IVAX Holdings C.I.
- --------------------------------------------------------------------------------
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [_]
2
(b) [X]
- --------------------------------------------------------------------------------
SEC USE ONLY
3
- --------------------------------------------------------------------------------
SOURCE OF FUNDS
4
AF
- --------------------------------------------------------------------------------
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
5 2(d) or 2(e) [_]
- --------------------------------------------------------------------------------
CITIZENSHIP OR PLACE OF ORGANIZATION
6
Cayman Islands
- --------------------------------------------------------------------------------
SOLE VOTING POWER
7
NUMBER OF 0
-------------------------------------------------------------
SHARES SHARED VOTING POWER
8
BENEFICIALLY 62,565,840 Shares of common stock (including Shares
represented by ADSs)
OWNED BY -------------------------------------------------------------
SOLE DISPOSITIVE POWER
EACH 9
0
REPORTING -------------------------------------------------------------
SHARED DISPOSITIVE POWER
PERSON 10
62,565,840 Shares of common stock (including Shares
WITH represented by ADSs)
- --------------------------------------------------------------------------------
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
11
62,565,840 Shares of common stock (including Shares represented by ADSs)
- --------------------------------------------------------------------------------
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [_]
12
- --------------------------------------------------------------------------------
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
13
19.8%
- --------------------------------------------------------------------------------
TYPE OF REPORTING PERSON*
14
CO
- --------------------------------------------------------------------------------
The Tender Offer Statement on Schedule TO (the "Schedule TO") relates to
an offer by IVAX Holdings C.I. ("Purchaser"), a Cayman Islands company and a
wholly-owned subsidiary of IVAX Corporation, a Florida corporation ("IVAX"), to
purchase all outstanding American Depositary Shares (the "ADSs") of Laboratorio
Chile S.A. ("LabChile") and all shares of common stock, no par value (the
"Shares") of LabChile held by U.S. holders within the meaning of Rule 14d-1(d)
of the Exchange Act, in each case not beneficially owned by IVAX or its
affiliates, upon the terms and subject to the conditions set forth in the U.S.
Offer to Purchase dated July 31, 2001 (the "Offer to Purchase"), and in the
related ADS Letter of Transmittal and Form of Acceptance, copies of which are
attached hereto as Exhibits (a)(1), (a)(2) and (a)(8) (which are collectively
referred to as the "U.S. Offer Documents"). Each ADS represents 20 shares. This
Schedule TO also constitutes Amendment No. 1 to the Schedule 13D with respect to
LabChile filed by IVAX and the Purchaser as the final amendment to the Schedule
TO filed by IVAX and the Purchaser on July 2, 2001.
The information in the U.S. Offer Documents, including the Schedules
thereto, are hereby expressly incorporated herein by reference in response to
all the items of this Schedule TO, except as otherwise set forth below.
2
ITEM 4. TERMS OF THE TRANSACTION.
(a)(1)(ix), (x) and (xi) Not Applicable.
(b)(2) Not Applicable.
ITEM 6. PURPOSES OF THE TRANSACTION AND PLANS OR PROPOSALS.
(c)(1), (c)(2) and (c)(5) Not Applicable.
ITEM 7. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.
(b) None.
(d) Not Applicable.
ITEM 10. FINANCIAL STATEMENTS
Not Applicable.
ITEM 12. EXHIBITS.
(a)(1) Offer to Purchase dated July 31, 2001
(a)(2) Form of ADS Letter of Transmittal
(a)(3) Form of Notice of Guaranteed Delivery
(a)(4) Form of Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and other Nominees for Shares of Common Stock
(a)(5) Form of Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and other Nominees for American Depositary Shares
(a)(6) Form of Letter to Clients for Shares of Common Stock
(a)(7) Form of Letter to Clients for American Depositary Shares
(a)(8) Form of Acceptance
(a)(9) Guidelines for Certification of Taxpayer Identification Number
on Substitute Form W-9.
(a)(10) Press Release Issued by IVAX Corporation on July 31, 2001
ITEM 13. INFORMATION REQUIRED BY SCHEDULE 13E-3.
Not applicable.
3
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this Schedule TO is true, complete and
correct.
IVAX Corporation
July 31, 2001 By: /s/ Neil Flanzraich
-----------------------------------
Neil Flanzraich
Vice Chairman and President
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this Schedule TO is true, complete and
correct.
IVAX Holdings C.I.
July 31, 2001 By: /s/ Neil Flanzraich
-----------------------------------
Neil Flanzraich
President
4
Exhibit Index
Ex. No. Exhibit Description
- -------- -------------------
99(a)(1) Offer to Purchase dated July 31, 2001
99(a)(2) Form of ADS Letter of Transmittal
99(a)(3) Form of Notice of Guaranteed Delivery
99(a)(4) Form of Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and other Nominees for Shares of Common Stock
99(a)(5) Form of Letter to Brokers, Dealers, Commercial Banks, Trust
Companies and other Nominees for American Depositary Shares
99(a)(6) Form of Letter to Clients for Shares of Common Stock
99(a)(7) Form of Letter to Clients for American Depositary Shares
99(a)(8) Form of Acceptance
99(a)(9) Guidelines for Certification of Taxpayer Identification Number on
Substitute Form W-9.
99(a)(10) Press Release Issued by IVAX Corporation on July 31, 2001